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Background:  MEF2C is an important regulator of many developmental programs. 
Results:  Alternative splicing of the  exon of MEF2C regulates myogenesis.  Loss of SRPK3 in 
rhabdomyosarcoma cells inhibits this splicing and blocks differentiation.  
Conclusion:  MEF2C2 promotes myogenesis and restoration of MEF2C2 in rhabdomyosarcoma cells 
inhibits growth.  
Significance:  Defining the function and deregulation of MEF2C2 enhances the understanding of 
normal myogenesis and RMS tumorigenesis. 
 
ABSTRACT 
Rhabdomyosarcoma (RMS) is the most 
common soft tissue sarcoma in children.  Many 
cellular disruptions contribute to the 
progression of this pediatric cancer including 
aberrant alternative splicing.  The MEF2 
family of transcription factors regulates many 
developmental programs, including 
myogenesis.  MEF2 gene transcripts are subject 
to alternate splicing to generate protein 
isoforms with divergent functions.  We found 
that MEF2C1 was the ubiquitously expressed 
isoform which exhibited no myogenic activity 
and that MEF2C2, the muscle specific 
MEF2C isoform, was required for efficient 
differentiation.  We showed that exon  in 
MEF2C was aberrantly alternatively spliced in 
RMS cells, with the ratio of highly 
downregulated in RMS cells compared with 
normal myoblasts.  Compared with MEF2C2,  
MEF2C1 more strongly interacted with and 
recruited HDAC5 to myogenic gene promoters 
to repress muscle specific genes.  
Overexpression of the MEF2C2 isoform in 
RMS cells increased myogenic activity and 
promoted differentiation in RMS cells.  We 
have also identified a serine protein kinase, 
SRPK3, which was downregulated in RMS cells 
and found that expression of SRPK3 promoted 
the splicing of the MEF2C2 isoform and 
induced differentiation.  Restoration of either 
MEF2C2 or SPRK3 inhibited both 
proliferation and anchorage independent 
growth of RMS cells.  Together, our findings 
indicate the alternative splicing of MEF2C 
plays an important role in normal myogenesis 
and RMS development.  Improved 
understanding of alternative splicing events in 
RMS cells will potentially reveal novel 
therapeutic targets for RMS treatment. 
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Introduction  
 The myocyte enhancer factor 2 (MEF2) is 
a regulator of many developmental programs, 
including myogenesis (1).  MEF2 is encoded by 
four vertebrate genes which encode MEF2A, 
MEF2B, MEF2C and MEF2D.  The MEF2 family 
is expressed in distinct but overlapping temporal 
and spatial expression patterns in the embryo and 
adult (2).  Both MEF2C and MEF2D are 
implicated in myogenesis (3,4), which is 
controlled by the concerted activity of the 
myogenic regulatory factors (MRFs), a group of 
four highly related bHLH transcription factors 
composed of Myf5, MyoD, Myf6, and myogenin 
(5).  MEF2 factors alone do not possess myogenic 
activity, but work in combination with the MRFs 
to drive the myogenic differentiation program (6).   
 MEF2 proteins control differentiation, 
proliferation, survival and apoptosis in a wide 
range of cell types.  The N-terminus of the MEF2 
proteins contains a highly conserved MADS box 
and an immediately adjacent motif termed the 
MEF2 domain.  Together, these motifs mediate 
dimerization, DNA binding and co-factor 
interactions (7).  The C-terminus of the MEF2 
proteins is highly divergent among the family 
members and functions as the transcriptional 
activation domain.  MEF2 proteins function as 
endpoints for multiple signaling pathways and 
confer a signal-responsiveness to downstream 
target genes.  MAP kinase pathways are known to 
converge on MEF2 (8,9), resulting in a 
phosphorylation of the transcriptional activation 
domain of MEF2 which augments its 
transcriptional activity.  Calcium signaling 
pathways also modulate MEF2 activity through 
multiple mechanisms (10-13).  The activity of 
MEF2 is tightly controlled by class II HDACs, 
which bind to the MADS domain and promote the 
formation of multiprotein repressive complexes on 
MEF2 dependent genes (14).  Phosphorylation of 
class II HDACs is mediated by calcium regulated 
protein kinases, which promote the nuclear-
cytoplasmic shuttling of the HDACs and 
subsequent activation of MEF2C (14,15).   
 Each of the MEF2 genes are subject to 
extensive alternative splicing.  MEF2C contains 
three alternative exons: the mutually exclusive 
exons 1/2, the skipping/inclusion exon  and 
the 3' splice site region .  The 1 domain is 
expressed ubiquitously, while the 2 domain is 
strongly expressed in skeletal muscle (16).  The 
function of the  domain is unknown, although it 
has been shown that isoforms entirely lacking the 
 domain have enhanced activity (17).  Inclusion 
of the  exon has been described in neural cells 
(16,18) and the presence of the -exon in MEF2C 
was found to strongly activate MEF2C responsive 
reporters (19).  The  domain, generated by 
alternative splice site acceptors, has an inhibitory 
effect on the activity of MEF2C and isoforms 
lacking this domain better synergize with MyoD 
(20).  The use of alternative isoforms in skeletal 
muscle differentiation  has been recently shown 
for MEF2D, which promotes late muscle 
differentiation through use of alternative isoforms 
which generates a muscle specific MEF2D2 
isoform (21), which binds to the co-activator 
ASH2L and is resistant to phosphorylation by 
PKA and association with HDACs (22). 
 Rhabdomyosarcoma (RMS) is a highly 
malignant tumor that is the most common form of 
soft tissue tumors in children.  It is thought to arise 
as a consequence of myogenic precursors failing 
to differentiate into normal muscle (23).   There 
are two major histological categories of RMS, the 
embryonal (ERMS) and alveolar (ARMS) 
subtypes.  The more common form of the disease 
is the ERMS subtype.  ARMS, the more 
aggressive form of RMS, is characterized by 
chimeric transcripts that fuse the 5’ DNA binding 
domain of PAX3 or PAX7, respectively, to the 
transactivation domain of a forkhead transcription 
factor, creating novel PAX3/7-FOXO1 fusion 
proteins (24,25). 
 Rhabdomyosarcoma tumors express the 
myogenic regulatory factors, but the MRFs are 
unable to promote differentiation  (26).  Indeed, 
MyoD and myogenin are used as diagnostic 
markers for RMS as they are expressed in almost 
every RMS tumor including both major 
histological subtypes, embryonal RMS (ERMS) 
and alveolar RMS (ARMS) (27).   Many blocks to 
differentiation have been described and were the 
subject of a recent review (26). Exogenous 
expression of MEF2C (28) or MEF2D (29) can 
promote differentiation in RMS cells.   
 We have shown that the muscle specific 
MEF2C isoform (MEF2C2) was required for 
efficient differentiation of skeletal muscle cells 
and that this isoform was highly downregulated in 
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RMS cells.  MEF2C isoforms containing the 2 
exon have potent myogenic activity as assayed by 
muscle specific gene reporters,  muscle specific 
gene expression and myotube formation, while 
isoforms containing 1 or lacking the domain 
did not.  Despite the robust expression of 
MEF2C1 in RMS cells, restoration of the 
MEF2C2 isoform promoted RMS differentiation 
and myotube formation.  The MEF2C1 isoform 
had an enhanced association with HDAC5, which 
resulted in enhanced recruitment of class II 
HDACs to target promoters in the presence of 
MEF2C1.  We found that the alterative splicing 
of the 1/2 exon of MEF2C was controlled by 
the protein kinase SRPK3, which is specific for 
the SR (serine/arginine-rich domain) family of 
transcription factors, including the splicing factor 
ASF.  We showed that SRPK3 was downregulated 
in RMS cells.  Exogenous expression of SRPK3 in 
RMS promoted the splicing of the MEF2C2 
isoform, induced expression of muscle specific 
genes and drove the formation of myotubes.  
Exogenous expression of MEF2C2 or SRPK3  
inhibited the proliferation and anchorage 
independent growth of RMS cells.   
 
Experimental procedures 
Cell Culture   
 RD (ATCC), SJRH30 (RH30) cells (ATCC), 
C2C12 myoblasts (ATCC), 10T1/2 cells (ATCC) 
and HEK293 cells (ATCC) were grown in 
Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum 
(Hyclone) according to standard protocols.  To 
induce differentiation of C2C12 myoblasts into 
myotubes, cells were grown to 70% confluence 
and the media switched to DMEM supplemented 
with 2% horse serum (Hyclone).  C2C12 cells 
were grown in differentiation medium for the 
number of days indicated in each experiment.   
 
Cloning 
Murine Mef2C2 (mMef2C2) and Srpk3 were 
PCR amplified from cDNA reverse transcribed 
from RNA isolated from C2C12 cells 
differentiated for four days.  Human MEF2C 
isoforms (hMEF2C) were PCR amplified from 
cDNA generated from RNA isolated from human 
myoblasts (gift of Denis Guttridge, Ohio State 
University), RH30 cells or HEK293 cells.  A 
common primer set, MEF2C TOPO F 5' 
ATGGGGAGAAAAAAGATTCAGA 3' and 
MEF2C TOPO R 5' 
TCATGTTGCCCATCCTTCA 3', was used to 
amplify both mMef2C and hMEF2C.  Each of the 
PCR amplified fragments were cloned into the 
pEF6/V5 His TOPO TA expression vector and the 
clones confirmed by sequencing. 
 
Western Blot Analysis 
 Cell extracts were made by lysing PBS 
washed cell pellets in radio-immunoprecipitation assay 
buffer (RIPA) supplemented with protease inhibitors 
(Complete protease inhibitor, Roche Diagnostics).  
Following incubation on ice, clear lysates were 
obtained by centrifugation. Protein concentrations 
were determined by Bradford’s assay (Bio-Rad). For 
each sample, 30 µg of protein was loaded on each gel. 
Proteins were transferred onto a PVDF membrane 
using a tank blotter (Bio-Rad). The membranes were 
then blocked with 5% milk in 1X Tris buffered saline 
plus Tween 20 (TBST) and incubated with primary 
antibody overnight at 4ºC.  Membranes were then 
washed with 1X TBST before incubation with the 
corresponding secondary antibody.  Membranes were 
washed again with 1X TBST, incubated with 
chemiluminescent substrate according to 
manufacturer's protocol (SuperSignal, Pierce) and 
visualized by autoradiography.  The antibodies used 
include anti- MEF2C (D80C1, Cell Signaling), anti-
HDAC5 (Cell Signaling), anti-V5 (Rockland), anti-
MHC (MF-20, Developmental Studies Hybridoma 
Bank) and anti-GAPDH (Millipore).   
 
Gene expression analysis 
 RNA was isolated from cells by Trizol 
extractions (Invitrogen).  Following treatment with 
DNase (Promega), two micrograms of total RNA 
was reversed transcribed with MultiScribe™ 
MuLV reverse transcriptase (Applied Biosystems). 
cDNA equivalent to 40 ng was used for 
quantitative polymerase chain reaction (qPCR) 
amplification (Applied Biosystems) with SYBR 
green PCR master mix (Applied Biosystems). 
Samples in which no reverse transcriptase was 
added (no RT) were included for each RNA 
sample.  The relative levels of expression of genes 
were normalized according to those of 
hypoxanthine guanine phosphoribosyl transferase 
(HPRT)  qPCR data were calculated using the 
comparative Ct method (Applied Biosystems). 
 4 
 
Standard deviations from the mean of the [Δ] Ct 
values were calculated from three independent 
RNA samples.  Primers corresponding to the 
indicated genes were as described (30).  Where 
possible, intron spanning primers were used.  All 
quantitative PCR was performed in triplicate and 
three independent RNA samples were assayed for 
each time point.  For measurements of relative 
gene expression (fold change), a fold change was 
calculated for each sample pair by dividing the 
mRNA expression values of each sample pair. 
Each experimental fold change was then 
normalized to the fold change observed at HPRT.   
 
Chromatin immunoprecipitation 
ChIP assays were performed and 
quantified as described previously (31) with the 
following modifications: 1x107 cells were used for 
each immunoprecipitation and protein A agarose 
beads (Invitrogen) were used to 
immunoprecipitate the antibody:antigen 
complexes.  The following antibodies were used:  
HDAC5 (Cell Signaling), HDAC4 (Cell 
Signaling) and rabbit IgG (Santa Cruz 
Biotechnology) as a non-specific control.   Primers 
corresponding to the LMOD2 and CDKN1A 
promoters were as described (32).  The real time 
PCR was performed in triplicate.  Values of [Δ] 
[Δ] Ct were calculated using the following formula 
based on the comparative Ct method: Ct, template 
(antibody) - Ct, template (IgG) = [Δ] Ct. Fold 
enrichments were determined using the formula : 2 
- [Δ] Ct. (experimental)/2 -[Δ] Ct  (reference, CHR19).  
Standard error from the mean was calculated from 
replicate [Δ][Δ] Ct values obtained from at least 
three individual experiments.  
 
Cell Transfections and Luciferase Assays 
Cells were transfected with calcium 
phosphate according to standard protocols.  The 
plasmids pEF6-mMef2C2,-, +, pEF6-
hMEF2C1,-, +, pEF6-hMEF2C1,-, -, 
pEF6-hMEF2C2,-, - , pEF6-hMEF2C2,-, 
+, and pEF6-hMEF2C-,-, + were used for 
expressing different isoforms of mMef2C and 
hMEF2C.  pEF6-SRPK3 was used to express 
SRPK3.  The plasmid pEMCIIs (provided by 
Andrew Lassar, Harvard Medical School) was 
used for expressing MyoD.  Luciferase activity 
was determined using the Dual-Luciferase 
Reporter Assay System (Promega).  RH30 or RD 
cells were seeded at a density of 5x103 cell per 
well in 96 well plates and transfected with 0.4 ug 
of DNA.  Transfections were normalized to 
Renilla luciferase.  Transfections were performed 
in triplicate and all data sets were repeated at least 
twice.  
 
Stable Cell Lines 
 Stable  C2C12, RD and RH30 cell lines 
overexpressing exogenous MEF2C or SRPK3 were 
constructed by transfecting cells with linearized pEF-
V5 His vector (empty vector), linearized pEF-MEF2C 
or linearized pEF-SRPK3 and selecting for blasticidin 
(10 ug/ml) resistant colonies.  Murine clones of 
Mef2C1 and Mef2C2 were used in murine cell lines 
and human clones were used in human cell lines.  
Individual clones were isolated and propagated.   
   
Immunohistochemistry 
Cells were grown on cover slips, fixed 
with paraformaldehyde, incubated with goat serum 
supplemented with 1.0 % NP-40 for one hour and 
washed with PBS.  Primary antibodies against 
myosin heavy chain (1:100, MF20, Developmental 
Studies Hybridoma Bank) were incubated for 2 
hours at room temperature, washed with PBS and 
detected by Alexa Fluor-488 goat anti-mouse 
antibody (1:500, Invitrogen).  Cell nuclei were 
then stained by incubating with DAPI (1 M, 
Invitrogen) for 5 min. 
 
Proliferation 
Cells were seeded in a six well plate at 
6x104 per well and harvested every two days for 
cell counts with a hemocytometer.  All counts 
were performed in triplicate and individual 
experiments repeated three times.  
 
Soft agar assay 
Soft agar assays were carried out in 60 
mm dishes in which 2 ml of 0.7% Noble agar 
(USB) in 1X DMEM with 10% FBS was overlaid 
with 2 ml of 0.35% agar in 1X DMEM with 10% 
FBS containing 3x105 cells. RD and RH30 cells 
transected with pEF6 V5 His(vector), MEF2C2 
and SRPK3  were grown to 70% confluence, 
trypsinized, and dispersed. Cells of each clone 
were plated in triplicate. 1 ml of culture medium 
was added to the top of each plate every 5 days 
and cells were grown at 37oC for 30 days.  The 
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plates were stained with 1 ml of 0.05% Crystal 
Violet (Fisher) for > 1 hour and colonies were 
counted using a dissecting microscope.  
Statistics  
 qPCR data are presented as means ± standard 
deviation (SD).  Statistical comparisons were 
performed using unpaired two-tailed Student's t tests, 
with a probability value of <0.05 taken to indicate 
significance. 
 
Results 
The muscle specific 2 exon of MEF2C is not 
expressed in RMS cells 
 To understand the blocks to differentiation 
in RMS cells, we undertook an analysis of the 
MEF2 family in RMS.  During the course of this 
work, we found that both RD and RH30 cells 
highly expressed MEF2C (29), although MEF2C 
has also been reported to be downregulated in RD 
cells (28).  MEF2C has been shown to play an 
important role in myogenesis and MEF2C is 
subject to alternative splicing by 
exclusion/inclusion of exon α1/2, exon β and exon 
γ (Figure 1A).  The exon β has been reported to 
enhance MEF2C activity, while exon γ plays an 
inhibitory role. However, the function of the 
mutually exclusive exons α1/α2 has not yet been 
characterized.  To characterize the function of the 
MEF2C isoforms, we cloned MEF2C from RH30 
cells, human myoblasts, C2C12 cells and HEK293 
cells.  The isoforms recovered from each cell type 
are shown in Figure 1B.  As has been previously 
observed (16), the muscle specific2 exon was 
only found in mRNA from C2C12 cells and 
human myoblasts.  The transcripts from C2C12 
cells each contained the inhibitory  domain, while 
human myoblast RNA produced transcripts with 
or without the  domain.  Both RD and RH30 cells 
contained the 1 exon with or without the gamma 
( domain.   HEK293 cells expressed isoforms 
either with the 1 domain or lacking the  domain 
entirely.  The transcripts containing the 1 domain 
lacked the  domain, and the transcripts without 
the  domain contained the  domain.  Consistent 
with the prior analyses which identified the  exon 
exclusively in neuronal tissue (16,18), we 
identified no transcripts which contained the  
domain from any of the cell types in our study.   
 We sought to verify our results using 
reverse transcription PCR (RT-PCR) to detect the 
expression of exon α and exon β by exon specific 
primers in normal muscle and RMS cells. The 
location of the primers is shown in Figure 2A.  
Consistent with the results shown in Figure 1, we 
found that the MEF2C1 exon was ubiquitously 
expressed in both proliferating and differentiated 
C2C12 cells, human myoblasts and the RMS cell 
lines (Figure 2B).  The MEF2C2 exon was only 
expressed in differentiated C2C12 cells and human 
myoblasts (Figure 2B).  Expression of the exon 
could not be detected in any of the samples tested 
here (Figure 2C).  To verify detection of the  
exon, we also assayed samples from the brain, 
induced pluripotent stem (iPS) cells and neural 
progenitor cells (NPC) derived from iPS cells (33).  
As anticipated, we found that brain and NPC cells 
expressed the  exon, while iPS cells did not 
(Figure 2C). 
 To further clarify our results, we used 
quantitative RT-PCR (qRT-PCR) to quantitate the 
expression pattern of MEF2C1/2 isoforms 
during normal myogenesis and in RMS cells.  
Using primers specific to the1 or 2 domain of 
MEF2C, we examined expression in C2C12 cells 
throughout a time course of differentiation.  We 
found that the transcript for MEF2C1 was 
expressed in proliferating C2C12 cells (UD) and 
expression did not change significantly when cells 
were differentiated (Figure 2D).  In RMS cells, 
expression of MEF2C1 was compared to the 
expression levels found in human myoblast RNA.  
We found that both RD and RH30 cells expressed 
very high transcript levels of MEF2C1 (Figure 
2E).  When the expression of MEFC2 was 
examined, the expression was very low in 
proliferating C2C12 cells, but the ratio of 2 
expression vs 1 expression sharply increased 
upon differentiation (Figure 2F).  For RMS cells, 
very low expression of MEF2C2 was observed 
compared to the expression observed in human 
myoblast RNA and the ratio of 2/1 expression 
did not increase significantly upon differentiation 
(Figure 2G).   
 
MEF2C2 has myogenic activity while MEF2C1 
does not. 
 We next compared the myogenic activity 
of the MEF2C isoforms on a muscle specific 
reporter.  We chose a muscle specific reporter 
which contains the Leiomodin2 (Lmod2) promoter 
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fused to  luciferase, Lmod2-luc, which we have 
used previously to characterize the activity of the 
MRFs and MEF2D (29,34).   The Lmod2-luc 
reporter shows very low activity in proliferating 
cells and is strongly upregulated upon 
differentiation.  Transfection of MyoD or 
myogenin activate the reporter.  Thus, we assayed 
for the activity of  the Lmod2-luc reporter with 
MyoD alone, and in combination with each of the 
MEF2 isoforms in 10T1/2 cells, a fibroblast cell 
line considered poised for activation of muscle 
specific genes.  We found that MEF2C1 did not 
enhance the activity of the reporter and in fact had 
a mild inhibitory effect (Figure 3A).  The addition 
of the  domain was also modestly inhibitory, as 
has been previously seen.  The isoform lacking the 
 domain did not significantly inhibit or activate 
the Lmod2-luc reporter.  The MEF2C2 isoform 
strongly activated the Lmod2-luc reporter.  
Addition of the  domain again lead to a modest 
inhibition, but the  domain containing isoform 
still robustly activated the Lmod2-luc reporter.  
The work indicates that transcripts including 2 
are required for MEF2C myogenic enhancing 
activity, among which the isoform without  
domain is a modestly stronger than that with  
domain.  Transcripts with the 1 exon appear to 
inhibit the myogenic activity of MyoD.    
 To confirm these results, we next assayed 
for the activity of the MEF2C isoforms on 
endogenous gene expression.  10T1/2 cells were 
tranfected with constructs expressing MyoD in 
combination with constructs expressing either 
MEF2C1 or MEF2C2.  Gene expression 
analysis confirmed the expression of each MEF2C 
isoform (Figure 3B).  We found that transfection 
of MEF2C2 with MyoD strongly induced muscle 
specific gene expression, including myosin light 
chain, phosphorylatable, fast (Mylpf), creatine 
kinase, muscle (Ckm) and troponin T, type 1 
(Tnnt1), while MEF2C1 had no activity (Figure 
3C). 
 Our data are consistent with previous 
findings which show that muscle expresses both 
MEF2C2 and MEF2C1 (16,18).  To determine 
the effect of each isoform in muscle, MEF2C1 
and MEF2C2 were individually ectopically 
expressed in C2C12 cells.  Proliferating C2C12 
cells were transfected with plasmids expressing 
MEF2C1 or MEF2C2 and then induced to 
differentiate.  Expression of the individual 
isoforms was confirmed by qRT-PCR (Figure 4A).  
Expression of the exogenous epitope tagged 
MEF2C isoforms was also confirmed by western 
blot analysis (Figure 4B).  When differentiation 
specific gene expression was examined, we found 
that exogenous expression of MEF2C2 
stimulated the expression of actin (Acta1), 
troponin 1 type 2 (Tnni2) and leiomodin 2 
(Lmod2), while the MEF2C1 isoform had a 
modest inhibitory effect (Figure 4C).  The effect 
on differentiation was also assayed by 
immunostaining for expression of myosin heavy 
chain (MHC), which is commonly used as a 
marker for myogenesis.  We found that ectopic 
expression of MEF2C2 significantly stimulated 
the formation of myosin heavy chain positive 
myotubes, while the expression of MEF2C1 was 
inhibitory for myotube formation (Figure 4D).   
   To determine if MEF2C2 could rescue 
the MRF dependent activation of muscle specific 
genes in RMS, we first asked if MEF2C2 could 
activate the Lmod2 reporter in RD cells.  We 
found that MEF2C2 robustly induced the Lmod2 
reporter, while the MEF2C1 isoform was not 
able to activate the reporter (Figure 5A).  
Consistent with our results in Figure 3, we found 
that MEF2C2 robustly stimulated the Lmod-luc 
reporter in RD cells.  The isoform lacking an  
domain did modestly activate the reporter (~2 
fold), but not nearly to the degree as the 
MEF2C2 isoform.  Next, we examined the effect 
on the expression of differentiation specific genes 
in RD cells and found that MEF2C2 stimulated 
the expression of LMOD2, TNNI2 and CDKN1A 
(p21) (Figure 5B).  The cell cycle regulator p21 is 
required for terminal differentiation (35) and is 
regulated in part by MyoD in muscle (36).  To 
determine if the MEF2C2 isoform could promote 
differentiation in RMS cells, exogenous 
MEF2C1 and MEF2C2 were expressed in RD 
cells and myotube formation assayed by myosin 
heavy chain (MHC) immunohistochemistry.  We 
found that MEF2C2 expression markedly 
induced differentiation in RD cells (Figure 5C). 
 
MEF2C1 preferentially associates with HDAC5
 To begin to address how the 2 exon of 
MEF2C promotes myogenesis while the 1 exon 
does not, we asked if the association with histone 
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deacetylases (HDACs) with each isoform was 
distinct.  MEF2 is well known to interact with 
histone deacetylases (1), and the differential 
phosphorylation of the 1/2 exon of MEF2D 
alters the association with HDACs (22).  Thus, we 
asked if a difference in HDAC association could 
be observed for MEF2C1 vs MEF2C2.  
HEK293 cells, which express endogenous 
MEF2C1, were transfected with constructs 
expressing MEF2C1 or MEF2C2.  MEF2C 
proteins were immunoprecipitated with antibodies 
against MEF2C and the immunoprecipitate probed 
for HDAC5.  We found that the cells transfected 
with a plasmid expressing MEF2C2 
immunoprecipitated HDAC5 less robustly than 
cells transfected with a plasmid expressing 
MEF2C1 (Figure 6A).  The antibody used for the 
immunoprecipitation could immunoprecipitate 
both MEF2C1 and MEF2C2, so it is possible 
that the differential association of HDAC5 might 
be more significant than that indicated by our 
experiment as HEK293 cells have endogenous 
levels of MEF2C1.  Selective 
immunoprecipitation of the isoforms using epitope 
tags on the constructs was attempted, but non-
specific bands in the immunoprecipitate precluded 
analysis of HDAC association.   
 To understand if the differential 
association of HDAC5 observed would influence 
HDAC recruitment to target genes, we performed 
chromatin immunoprecipitation (ChIP) assays for 
HDAC5 in RD cells, which express MEF2C1, 
transfected with a vector control  or with a 
construct expressing exogenous MEF2C2.  We 
found that HDAC5 could be detected on muscle 
specific promoters in RD cells transfected with 
vector, but this association was decreased when 
MEF2C2 was expressed (Figure 6B).  The 
decrease in HDAC recruitment was also observed 
at the CDKN1A (p21) promoter.  We also 
examined the recruitment of HDAC4, an 
additional class II HDAC, by ChIP assays and 
found that HDAC4 association was also disrupted 
by MEF2C2 expression (Figure 6C).  Our data 
indicate that MEF2C2 may promote muscle gene 
expression at least in part by reducing the 
recruitment of HDACs to target promoters and 
thus promoting gene activation. 
SRPK3 is downregulated in RMS cells 
 As our data suggested that the lack of 
expression of MEF2C2 in RMS cells might 
contribute to the block to differentiation in these 
cells, we sought to understand why the MEF2C2 
isoform was not expressed in RMS cells.  To 
address this, we attempted to identify the splicing 
factors which controlled the  isoform selection.  
Two bioinformatic databases, Expasy (37) and 
Uniprot (38), were used to predict the splicing 
factors which might recognize the  exon splice 
sites in MEF2C.  Both programs predicted the 
serine/arginine-rich splicing factor 1, SRSF1 
(ASF), which is activated by phosphorylation.  To 
initiate our analysis, we assayed for the expression 
of ASF in skeletal muscle and RMS cells.  We 
found that the expression of ASF is modestly 
upregulated during myogenesis (Figure 7A), 
consistent with a role for promoting the MEF2C1 
to MEF2C2 switch.  However, when RMS cells 
were analyzed for expression of ASF, we found 
that ASF was highly upregulated compared to 
human myoblasts (Figure 7B).  This result is 
consistent with many other studies which show 
that ASF is often highly upregulated in cancer 
(39). 
 We next looked for expression of 
upstream kinases required for activation of ASF.   
We choose SRPK3, a muscle specific protein 
kinase which is regulated by MEF2C in skeletal 
muscle (40).  As has been previously shown (40), 
SRPK3 was strongly upregulated during normal 
myogenesis (Figure 7C).   We also found that 
SRPK3 was downregulated in RMS cells (Figure 
7D).  To determine if SRPK3 was required for 
splicing of the MEF2C2 isoform, SRPK3 was 
depleted from C2C12 cells using shRNA 
constructs.  Multiple shRNA constructs were used 
independently and the results of two individual 
constructs are shown.  We found that the 
constructs depleted SRPK3 (Figure 7E) and 
inhibited splicing of the MEF2C2 isoform when 
assayed after two days of differentiation (Figure 
7F).   
 
SRPK3 activates the splicing of MEF2C2 and 
promotes differentiation in RMS cells 
 To determine if the downregulation of 
SRPK3 contributed to the isoform selection in 
MEF2C and the block to differentiation in RMS 
cells, we ectopically expressed SRPK3 in RD 
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cells.  The expression of SRPK3 was confirmed by 
qRT-PCR (Figure 8A).  The expression of the 
MEF2C1 and MEF2C2 isoforms was then 
analyzed and we found that expression of 
exogenous SRPK3 did not significantly alter the 
expression of the MEF2C1 isoform, but did 
strongly enhance expression of the MEF2C2 
isoform (Figure 8B).  To determine if the 
expression of SRPK3 could promote 
differentiation, we assayed these cells for 
differentiation specific gene expression including 
LMOD2, ACTA1, TNNT1 and CDKN1A.  We 
found that each of these genes were upregulated in 
cells expressing SRPK3 (Figure 8C), strongly 
suggesting the SRPK3 promotes differentiation 
specific splicing which allows expression of the 
appropriate transcripts required for differentiation.  
Differentiation was also assayed by 
immunostaining for MHC in RD cells transfected 
with expression constructs for vector, MEF2C2 
or SRPK3.  We found that MEF2C2 or SRPK3 
promoted robust MHC signal and the appearance 
of myotubes (Figure 8D).  To determine if SRPK3 
and MEF2C2 could also promote differentiation 
in ARMS cells, the above experiment was 
repeated in RH30 cells and again, robust 
expression of MHC was observed (Figure 8D). 
 Finally, we sought to understand if 
SRPK3 or MEF2C2 could inhibit the 
proliferation and tumorigenic growth of RMS 
cells.  RD cells expressing exogenous SRPK3 or 
MEF2C2 were assayed for proliferation and we 
found these cells had reduced proliferation rates 
when compared to the vector only controls (Figure 
9A).   To extend this result to the ARMS subtype 
of RMS, the proliferation assay was repeated in 
RH30 cells.  We found that exogenous expression 
of SRPK3 or MEF2C2 also inhibited the 
proliferation of RH30 cells (Figure 9B).  To 
determine if SRPK3 or MEF2C2 could inhibit 
anchorage independent growth of these cells, 
growth in soft agar media was assayed.  We found 
that RD cells expressing exogenous MEF2C2 or 
SRPK3 formed fewer colonies in soft agar media 
(Figure 9C) and the colonies which did form were 
smaller in size than that observed for the vector 
only controls (Figure 9D).  The data suggest that 
restoration of differentiation specific splicing may 
inhibit RMS tumor growth. 
Discussion 
 We show here that the 2 exon of MEF2C 
confers myogenic activity on MEF2C and results 
in differential HDAC recruitment to target 
promoters.  The expression of the MEF2C1 exon 
in RMS cells contributes to the lack of 
differentiation observed in those cells. The 
splicing of the 2 exon is promoted by SRPK3 
and restoration of SRPK3 or MEF2C2 in RMS 
cells enhances differentiation and inhibits 
proliferation and tumorigenic growth.  MEF2C has 
been previously shown to induce differentiation in 
RMS cells (28) and our results reveal that the 
deficiency in MEF2C activity is due to the lack of 
appropriate muscle specific splicing.   
 Defects in alternative splicing have been 
previously observed in RMS cells.  The oncogenes 
Murine Double Minute 2 (MDM2) and MDM4 
exhibit genotoxic-stress inducible splice forms in 
high risk metastatic disease represented by both 
ERMS and ARMS.  Expression of these alterative 
isoforms promotes metastatic behavior of tumor 
cells (41).   Multiple splicing isoforms of PAX3, 
PAX7 and the PAX-FOXO1 fusions have also 
been observed  in RMS and differences in the 
PAX7 splicing pattern between murine skeletal 
muscle and RMS tumors has been observed (42).  
To our knowledge, our work is the first to 
implicate the deregulation of a splicing factor in 
RMS.  We show here that SRPK3 is required for 
the isoform switch between MEF2C1 and 
MEF2C2, but likely controls the splicing of 
many other genes required for normal muscle 
differentiation.    
 A recent study has shown that the 
expression and alternative splicing of the MEF2 
genes are deregulated in muscle from 
neuromuscular disorder (NMD) patients, including 
DM1 and DM2 (43).  In DM, expression of a 224 
bp isoform encompassing exons 4A and 4B 
(corresponding to MEF2C1) was found to 
expressed in muscle while normal muscle 
contained a 217 bp isoform encompassing exon 5a 
(corresponding to MEF2C2) (43).  Our work 
suggests that expression of MEF2C1 in diseased 
muscle would prevent appropriate differentiation 
specific gene expression and contribute to the 
muscle dysfunction observed in the patients.    
 In a related study,  MEF2C was found to 
be deregulated in cardiac tissue of DM1 patients 
(44).   A screen of microRNAs revealed that 
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several miRNAs were differentially expressed in a 
mouse model of DM1, and many of these miRNAs 
were direct MEF2 transcriptional targets.  A down 
regulation of MEF2C and MEF2A was observed 
in both the mouse models and in human DM1 
cardiac tissues and restoration of MEF2C 
promoted expression of miRNA and mRNA 
targets in DM1.  Cardiac tissue is thought to 
express the1 isoform of MEF2C and it will be 
interesting to understand how alternative splicing 
of MEF2C contributes to the dysfunction of 
MEF2C observed in both cardiac and skeletal 
muscle tissue in DM1 patients. 
 It is intriguing that the MEF2D2 isoform 
has been recently shown activate differentiation 
specific transcription (22), while the ubiquitously 
expressed MEF2D1 form does not, similar to 
what we observed with MEF2C.  In the case of 
MEF2D, the activity was shown to be due to 
differential phosphorylation of the 1 vs 2 exon 
mediated by PKA (22,45).  Phosphorylation of the 
MEF2D1 isoform induces association with 
histone deacetylases (22).  We also see that the 1 
exon of MEF2C interacts preferentially with 
HDAC5 and induces the recruitment of HDAC5 
and HDAC4 to target promoters.  The basis of the 
differentiation interaction with HDAC5 is 
currently unclear for MEF2C, but it may also 
involve differential phosphorylation.  The 
phosphorylation of MEF2C is unlikely to be 
mediated by PKA as MEF2C has been reported to 
be a poor substrate for PKA (45) and the 1 exon 
of MEF2C does not contain consensus sites for 
PKA phosphorylation.   
 Besides the modulation of MEF2C by 
HDACs, we cannot rule out the potential 
regulation of 1/2 through differential 
interactions with other transcription factors and 
co-factors.  Many factors have been shown to 
modulate the activity of MEF2C during 
myogenesis including the myogenic regulatory 
factors, MyoD and myogenin (46); the  histone 
acetyltransferase, P300 (47); the steroid nuclear 
receptor coactivator NCOA2/GRIP-1 (48) and 
mastermind-like transcriptional coactivator 
(MAML) (49).  The calcineurin inhibitor Cabin1 
sequesters MEF2C in a transcriptionally inactive 
state which is released by an increase in 
intracellular calcium concentration (50).  The 
differential interaction of MEF2Cα1 and 
MEF2Cα2 with any of  these factors may 
contribute to the differences in myogenic activity 
we observe here.  Intriguingly, the MEF2C1 
domain has previously been shown to the target of 
the inhibitory effect of the Notch signaling 
pathway, which represses myogenesis (51).  The 
SVGHSPESEDKY region, which is uniquely 
present in MEF2Cα1 and not in MEF2Cα2, 
MEF2A, MEF2B or MEF2D, was shown to be 
required for the Notch mediated repression.  
Activated Notch signaling is common in many 
cancers and activated Notch has also been 
observed in RMS cells (52).  Thus, differential 
interactions of the MEF2C 1/2 isoforms with 
the Notch signaling pathway may also contribute 
to the differential activity of the isoforms.   The 
data shown here confirm that MEF2C constructs 
entirely lacking the domain have higher activity 
than the MEF2C1 isoform found in RMS cells.  
Further understanding of how elevated Notch 
signaling and MEF2C1 expression in RMS cells 
may contribute to the pathology of RMS is an 
important future direction for these studies.  
MEF2C is a direct transcriptional activator 
of many important developmental genes including 
c-jun (53) and matrix metalloproteinase 10 
(MMP10) (54). MEF2C is also a direct 
transcriptional activator of several miRNAs 
including miR-1, miR-21, miR-29, miR-30, miR-
133 (44).  It will be important to understand which 
isoform of MEF2C directs transcription of these 
important targets in each system and how the 
differential expression and regulation of the 
isoforms contributes to appropriate expression of 
MEF2C target genes. 
 While the MEF2C2 isoform was known 
to be expressed in skeletal muscle, our results 
reveal the requirement for the 2 exon for 
myogenesis and show that the differentiation 
defect in RMS cells extends to the muscle specific 
splicing patterns required for differentiation.   It 
will be important to further understand the 
deregulation of splicing factors such as SRPK3 in 
RMS as targeting these changes may offer novel 
therapeutic approaches for treating RMS.  
Defining the molecular basis for the myogenic 
activity of the2 exon of MEF2C and the 
differential recruitment of HDAC5 will also be 
important in understanding normal skeletal muscle 
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differentiation.  Understanding the function of 
the exon of MEF2C and how the appropriate 
splicing is achieved also contributes to the 
understanding of muscle dysfunction  in 
neuromuscular disease patients and  may  
potentially offer new therapeutic approaches for 
this disease as well.  
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Figure legends 
 
Figure 1.  MEF2C isoforms in muscle and RMS.  A.  A schematic of the MEF2C isoforms is 
shown.  The sequences of the exons are indicated below.  Murine and human sequences are 
indicated by m and h, respectively.  Amino acids which differ among the species are indicated in 
red.  B.  MEF2C isoforms identified in indicated cell lines.   The number beside each isoform 
indicates the number of individual isoform clones identified/total number of clones recovered. 
 
Figure 2.  Expression of the  and  exons of MEF2C in normal muscle and RMS.  A. 
Schematic of the exon structure of MEF2C with the location of the primers used to detect the 
exons indicated.  B.  The 1 exon of MEF2C is expressed ubiquitously in skeletal muscle, but 
the 2 exon is strongly upregulated during differentiation.  Exon expression was detected by RT-
PCR on the indicated samples.  Undifferentiated myoblasts are represented by UD and D 
represents the days of differentiation.  Human myoblasts are represented by h.m.  C.  The  exon 
is not expressed in muscle or RMS cells.  Exon expression was detected by RT-PCR on the 
samples indicated as in B. and from induced pluripotent stem (iPS) cells, neural progenitor cells 
(NPC) and brain. D.  Expression of the1 exon does not change during myoblast differentiation.   
Gene expression was assayed by qRT-PCR.  Error bars, SD.  ***P<0.001.  E.  The 1 exon is 
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highly expressed in RMS cells as assayed as in D.  F.  The 2 exon is upregulated during 
differentiation as assayed as in D.  Data are shown as the ratio of 2 expression relative to the 
expression of 1.  G.  The2 exon is highly down regulated in RMS and not induced by 
differentiation as assayed as in F.     
 
Figure 3.  MEF2C2 robustly enhances MRF activity, while MEF2C1 does not.  A.  
MEF2C2  stimulates the activity of MyoD on a muscle specific luciferase reporter construct. 
10T1/2 cells were transfected with the indicated constructs. Values are represented with respect 
to a luciferase vector with no promoter (pGL3 basic). pGL3 (+) represents a luciferase vector 
with the constitutive CMV promoter. Lmod2-luc represents a luciferase vector with a ~300 bp 
Leiomodin 2 (Lmod2) promoter. Error bars, SD.  ***P<0.001, **P<0.01.  B.  Confirmation of 
the expression of MEF2C1 and MEF2C2.  10T1/2 cells were transfected with expression 
constructs for MyoD, MEF2C1 and MEF2C2 as indicated and gene expression was 
determined by qRT-PCR for the indicated genes.  Vector represents a vector only transfection 
where the expression level was set to 1.  Error bars, SD.  ***P<0.001.  C.  MEF2C2 activates 
endogenous MRF target gene expression. 10T1/2 cells were transfected with expression 
constructs for MyoD, MEF2C1 and MEF2C2 and analyzed for the indicated genes as in B.   
 
Figure 4.  MEF2C2 promotes myogenesis in C2C12 cells.  A.  C2C12 cells were transfected 
with constructs expressing vector, MEF2C1 or MEF2C2.  Expression of the isoforms was 
confirmed by qRT-PCR.  Error bars, SD. ***P<0.001.  B.  Protein expression of the epitope 
tagged MEF2C isoforms was confirmed by western blot analysis.  C.  Differentiation specific 
gene expression is induced by overexpression of MEF2C2.  Gene expression was assayed for 
the indicated genes by qRT-PCR.  Error bars, SD. ***P<0.001.  D.  Over expression of 
MEF2C2 promotes myotube formation while MEF2C1 is inhibitory.  Cell lines in A. were 
differentiated for 3 days and immunostained with antibodies against MHC and counterstained 
with DAPI.  Images were taken at 200X magnification and scale bars represent 5 ms.  The data 
are quantitated in the lower panel. 
 
Figure 5.  MEF2C2 promotes differentiation in RMS cells.  A.  MEF2C2 activates a muscle 
specific reporter in RMS cells.  RD cells were transfected with the indicated constructs. Values 
are represented with respect to a luciferase vector with no promoter (pGL3 basic). pGL3 (+) 
represents a luciferase vector with the constitutive CMV promoter. Lmod2-luc represents a 
luciferase vector with a ~300 bp Leiomodin 2 (Lmod2) promoter. Error bars, SD.  ***P<0.001.  
B.  MEF2C2 promotes differentiation specific gene expression in RD cells.  RD cells were 
transfected with constructs expressing vector, MEF2C1 and MEF2C2.  Gene expression was 
assayed for the indicated genes by qRT-PCR.  Error bars, SD. ***P<0.001.  C.  MEF2C2 
promotes the expression of MHC in RD cells. RD cells expressing vector, MEF2C1 and 
MEF2C2 were immunostained for MHC and counterstained with DAPI.  Images were taken at 
100X magnification and scale bars represent 10 ms. 
 
Figure 6.  MEF2C1 recruits HDACs to target promoters.  A.  MEF2C1 interacts with HDAC5 
more robustly than MEF2C2.  HEK293 cells were transfected with expression constructs for 
MEF2C1 and MEF2C2, immunoprecipitated with an antibody against MEF2C and the blot 
probed with antibodies against HDAC5.  B.  MEF2C2 inhibits recruitment of HDAC5 to target 
 15 
 
promoters.  ChIP assays were performed on RD cells transfected with vector control or an 
expression construct for MEF2C2 with antibodies against HDAC5 and immunoprecipitated 
DNA probed with primers corresponding to the indicated promoters.  Error bars, S.D.  
***P<0.001.  C.  HDAC4 recruitment to target promoters is also inhibited by MEF2C2.  ChIP 
assays were performed as in B. except with antibodies against HDAC4. 
 
Figure 7.   Expression of splicing factors in skeletal muscle and RMS.  A.  ASF is modestly 
upregulated upon differentiation in C2C12 cells.  Gene expression was assayed by qRT-PCR and 
the days of differentiation are indicated.  Error bars, S.D.  B.  ASF is highly expressed in RMS 
cells.  Expression was assayed as in A.  C.  SRPK3 is robustly upregulated upon differentiation 
of C2C12 cells as assayed as in A.  D.  SRPK3 is highly downregulated in RMS cells as assayed 
as in A.  ***P<0.001.  E.  Depletion of SRPK3.  C2C12 cells were transfected individually with 
multiple shRNA contructs (shSRPK3) and stable transformants selected.  The two constructs 
shown are represented by (1) and (2).  Gene expression was assayed after two days of 
differentiation by qRT-PCR.  Error bars, S.D.  ***P<0.001.  F.  SRPK3 is required for 
MEF2C2 splicing.  Gene expression was assayed on the shSRPK3 depletions as in E.   
 
Figure 8.  SRPK3 and MEF2C2 promote differentiation of RMS cells.  A.  SRPK3 
overexpression in RD cells.  RD cells were transfected with a vector control or an expression 
construct for SRPK3 and assayed for gene expression by qRT-PCR. B.  SRPK3 induces the 
expression of MEF2C2.  Gene expression was assayed by qRT-PCR.  Error bars, S.D. 
***P<0.001.  C.  SRPK3 induces differentiation specific gene expression in RD cells.  Cells as 
in A. were assayed for gene expression by qRT-PCR for the indicated genes.  Error bars, S.D. 
***P<0.001.  D.  SRPK3 or MEF2C2 induce MHC expression in RMS cells.  RD (left panel) 
and RH30 cells (right panel) were transfected with a vector control or expression constructs for 
SRPK3 or MEF2C2 and immunostained for MHC and counterstained with DAPI.  Images were 
taken at 100X magnification and scale bars represent 10 ms.   
 
Figure 9.  SRPK3 and MEF2C2 inhibit growth of RMS cells.  A. SRPK3 or MEF2C2 inhibit 
the proliferation of RD cells.  RD expressing the indicated constructs were seeded at equivalent 
densities and harvested for cell counts every two days.  Error bars, SD.  B.  SRPK3 or MEF2C2 
inhibit the proliferation of RH30 cells.  Proliferation was assayed as in A.  C.  SRPK3 or 
MEF2C2 inhibit the number of anchorage independent colonies formed.  Error bars, S.D. 
***P<0.001.  D.  SRPK3 or MEF2C2 inhibit the size of anchorage independent colonies 
formed.  The largest colonies observed for each cell line are shown.     
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